Review article: The prothrombin time test as a measure of bleeding risk and prognosis in liver disease

Alimentary Pharmacology and Therapeutics

Volumn 26, Issue 2, 2007, Pages 141-148

  Tripodi, A ^a   Caldwell, S H ^b   Hoffman, M ^c   Trotter, J F ^d   Sanyal, A J ^e  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTICOAGULANT PROTEIN; ANTITHROMBIN; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING INHIBITOR; PROCOAGULANT; PROTEIN C; PROTEIN S; THROMBOPLASTIN;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER CIRRHOSIS; LIVER FUNCTION; MEASUREMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; REVIEW; RISK ASSESSMENT; RISK REDUCTION; VALIDATION STUDY;

HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; LIVER CIRRHOSIS; PROGNOSIS; PROTHROMBIN TIME; REFERENCE VALUES; RISK FACTORS;

EID: 34250845810     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03369.x     Document Type: Review

References (53)

1. Quick AJ. The prothrombin in hemophilia and in obstructive jaundice. J Biol Chem 1935 109 : 73 4.
2. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 126 (Suppl. 3 204S 33S. Erratum in: Chest 2005; 127: 415-6. Dosage error in text.
3. Kirkwood TB. Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemost 1983 49 : 238 44.
4. WHO. Expert Committee on Biological Standardisation. 33rd Report. WHO Technical Report Series 1983 687 : 81 105.
5. van den Besselaar AMHP, Poller L, Tripodi A. Guidelines for thromboplastins and plasmas used to control oral anticoagulant therapy (1999). WHO Technical Report Series 1999 889 : 64 93.
6. Tripodi A, Breukink-Engbers WGM, van den Besselaar AMHP. Oral anticoagulant monitoring by laboratory or near patient testing: what a clinician should be aware of. Sem Vasc Med 2003 3 : 243 54.
7. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transaction of the oesophagus for bleeding oesophageal varices. Br J Surg 1973 60 : 646 9.
8. Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000 31 : 864 71.
9. Hedner U, Erhardtsen E. Hemostatic disorders in liver disease. In : Schiff ER, Sorrell MF, Maddrey WC, eds. Diseases of the Liver, Philadelphia : Lippincott Williams and Wilkins, 2003 : 625 35.
10. White GC, Marder VJ, Colman RV, Hirsh J. Approach to the bleeding patient. In : Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis. Basic principles and clinical practice, 3rd edn. JB Lippincott Company : Philadelphia, 1994 : 965 8.
11. Bauer KA. Inherited and acquired hypercoagulable state. In : Lo Scalzo J, Schafer AJ, eds. Thrombosis and Hemorrhage, 3rd edn. Lippincott Williams and Wilkins : Philadelphia, 2003 : 648 84.
12. Carmassi F, De Negri F, Morale M, et al. Antithrombotic and antifibrinolytic effects of antithrombin III replacement in liver cirrhosis. Lancet 1997 349 : 1069.
13. Aurousseau MH, d'Angeli JL, Josso F. Antithrombin III versus prothrombin in liver cirrhosis. Haemostasis 1981 10 : 104 7.
14. Noris M, Remuzzi G. Uremic bleeding: closing the circle after 30 years of controversies? Blood 1999 94 : 2569 74.
15. Montalto P, Vlachogiannakos J, Cox DJ, et al. Bacterial infection in cirrhosis impairs coagulation by a heparin effect: a prospective study. J Hepatol 2002 37 : 463 70.
16. Tripodi A, Salerno F, Chantarangkul V, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005 41 : 553 8.
17. Tripodi A, Primignani M, Chantarangkul V, et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006 44 : 440 5.
18. Dahlback B. Progress in the understanding of the protein C anticoagulant pathway. Int J Hematol 2004 79 : 109 16.
19. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989 264 : 4743 6.
20. Deitcher SR. Interpretation of the international normalised ratio in patients with liver disease. Lancet 2002 359 : 47 8.
21. Schemmer P, Decker F, Dei-Anane G, et al. The vital threat of an upper gastrointestinal bleeding: Risk factor analysis of 121 consecutive patients. World J Gastroenterol 2006 12 : 3597 601.
22. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 1981 26 : 388 93.
23. Dillon JF, Simpson KJ, Hayes PC. Liver biopsy bleeding time: an unpredictable event. J Gastroenterol Hepatol 1994 9 : 269 71.
24. Segal JB, Dzik WH. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005 45 : 1413 25.
25. Boks AL, Brommer EJ, Schalm SW, et al. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology 1986 6 : 79 86.
26. Diaz LK, Teruya J. Liver biopsy. New Engl J Med 2001 344 : 2030.
27. Grabau CM, Crago SF, Hoff LK, et al. Performance standards for therapeutic abdominal paracentesis. Hepatology 2004 40 : 484 8.
28. Terjung B, Lemnitzer I, Dumoulin FL, et al. Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion 2003 67 : 138 45.
29. McGill DB, Rakela J, Zinsmeister AR, et al. A 21 year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990 99 : 1396 400.
30. Bravo AA, Sheth SG, Chopra S. Liver biopsy. New Engl J Med 2001 344 : 495 500.
31. Jacobs WH, Goldberg SB. Statement on outpatient percutaneous liver biopsy. Dig Dis Sci 1989 34 : 322 3.
32. Sue M, Caldwell SH, Dickson RC, et al. Variation between centres in technique and guidelines for liver biopsy. Liver 1996 16 : 267 70.
33. Caldwell SH, Hoffman M, Lisman T, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006 44 : 1039 46.
34. Lisman T, Bongers T, Adelmeijer J, et al. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006 44 : 53 61.
35. Hu K-Q, Yu AS, Tiyyagura L, et al. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am J Gastroenterol 2001 96 : 1581 6.
36. Bosch J, Thabut D, Bendtsen F, et al. European Study Group on rFVIIa in UGI Haemorrhage Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004 127 : 1123 30.
37. Lodge JP, Jonas S, Jones RM, et al. rFVIIa OLT Study Group Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl 2005 11 : 973 9.
38. Planinsic RM, van der Meer J, Testa G, et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl 2005 11 : 895 900.
39. Kravetz D, Sikuler E, Groszmann RJ. Splanchnic and systemic hemodynamics in portal hypertensive rats during hemorrhage and blood volume restitution. Gastroenterology 1986 90 : 1232 40.
40. Castaneda B, Morales J, Lionetti R, et al. Effects of blood volume restitution following portal hypertensive-bleeding in anesthetized cirrhotic rats. Hepatology 2001 33 : 821 5.
41. AuBuchon JP. Meeting transfusion safety expectations. Ann Intern Med 2005 143 : 537 8.
42. Amitrano L, Brancaccio V, Guardascione MA, et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology 2000 31 : 345 8.
43. Bauer KA. New anticoagulants: anti IIa vs anti Xa. Is one better? J Thromb Thrombolysis 2006 21 : 67 72.
44. Wiesner R, Edwards E, Freeman R, et al. United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor liver. Gastroenterology 2003 124 : 91 6.
45. Institute of Medicine Committee on Organ Procurement and Transplantation Policy. Organ Procurement and Transplantation: assessing current policies and the potential impact of the DHHS final rule. Washington, DC : National Academy Press 1999 : 1 29.
46. United Network for Organ Sharing. http://www.unos.org/ SharedContentDocuments/Revised_MELDPELD_2003(2).pdf (accessed December 20, 2005).
47. Trotter JF, Brimhall B, Arjal R. Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation. Liver Transpl 2004 10 : 995 1000.
48. Kenison J, Arjal R, Smith A, et al. Inter-laboratory variation in INR leads to clinically relevant changes in MELD score: survey of US clinical laboratories. Am J Transpl 2006 6 (Suppl. 2 333.
49. Robert A, Chazouilleres O. Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio. Hepatology 1996 24 : 1392 4.
50. Kovacs MJ, Wong A, MacKinnon K, et al. Assessment of the validity of the INR system for patients with liver impairment. Thromb Hemostas 1994 71 : 727 30.
51. Denson KW, Reed SV, Haddon ME, et al. Comparative studies of rabbit and human recombinant tissue factor reagents. Thromb Res 1999 94 : 255 61.
52. Mancuso A, Fung K, Cox D, et al. Assessment of blood coagulation in severe liver disease using thromboelastography: use of citrate storage versus native blood. Blood Coagul and Fibrinolysis 2003 14 : 211 6.
53. Tripodi A, Chantarangkul V, Primignani M, et al. The international normalized ratio calibrated for cirrhosis (INRliver) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology 2007 (in press).